Natco Pharma Stock Analysis || Natco Pharma Share Latest News скачать в хорошем качестве

Natco Pharma Stock Analysis || Natco Pharma Share Latest News

Will 2026 be the year Natco Pharma transforms or fades? In today’s video, we deep-dive into the complex 2026 outlook for Natco Pharma. While the company is facing a significant drop in profits compared to 2025 due to the "Revlimid Cliff," two massive catalysts are hiding in plain sight that could make this a game-changing year for long-term investors. What we cover in this video: The Semaglutide Showdown: Natco has officially challenged Novo Nordisk in the Delhi High Court. Can they launch generic Ozempic/Wegovy by March 2026? Agri-Business Demerger: Everything you need to know about the Crop Health Sciences spin-off and how it unlocks value for you. Earnings Normalization: Why the predicted dip to ₹1,275 Cr PAT isn't as bad as it looks. Technical Setup: Analyzing the current ₹900–₹950 price range and the latest analyst targets. The Verdict: Is Natco Pharma a 'Hold' for the dividend or a 'Buy' for the 2027 recovery? Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational, or personal use tips the balance in favor of fair use. Fundamental Analysis Playlist Link -    • Fundamental Analysis   Disclaimer:- Amitabh Mishra is only an Educational Platform and it is not registered under any of the SEBI Regulations. The Posts, References, and Calls shared in it are only meant for educational purposes and do not constitute any Trading or Investment advice. We make no representation as to the Timelines, Accuracy, Profitability, or Suitability of any content on this platform and can not be held liable for any irregularity or inaccuracy. Our research is solely for Educational Purposes only #NatcoPharma #Semaglutide #StockMarketIndia #PharmaStocks #ValueInvesting